Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Apr 07, 2016 12:19pm
89 Views
Post# 24741253

RE:DIABETES CASES QUADRUPLE

RE:DIABETES CASES QUADRUPLE Hi Jkj. Thanks for the link.

The diabetes ML and obesity relationship has been all over the media lately and of course has been well known by Resverlogix, Hepalink (based in China where diabetes mellitus is out of control and increasing), Eastern Capital and NGN for a number of years.

As we know, Resverlogix is exactly in the right position to capitalze on this with apabetalone (rvx-208) with it's 77% relative risk reduction (absolute risk reduction of 16% points = 21% - 5%) within patients with diabetes mellitus, CVD and  low HDL.

The diabetes mellitus, obesity and CVD problem is an extremely costly health care issue throughout the world and it will continue to grow. As the article indicates people must eat properly, excercise and reduce theiir weight.
  • This will not happen...people do not have the time, effort and will power to do it. Fried foods consumed with soda drinks with massive amounts of sugar will continue to fatten up the American population (and many other countries) and cause stress on their pancrease(s).
Therefore, fortunately for me and long share holders, the solution to avoiding MACE (major cardiovascular events) with be statins (Crestor - rosuvastatin) for LDL reduction in combination with apabetalone (rvx-208) to boast ApoA-l the most dominant component of functional HDL. As we know apabetalone impacts multiple pathways including modulating gene transcription and has effects on pathways known to play important roles in CVD risks including the complement, coagulation, inflammation, and metabolism as well as increasing levels of the apolipoprotein A-I (apoAI), the major protein in high density lipoprotein(HDL) resulting in reverse cholesterol transport.

From the article - Type 2 diabetes is a long-term condition characterized by insulin resistance. Patients can manage their diabetes with medication and diet, but the disease is often life-long and is a major cause of blindness, kidney failure, heart attacks, stroke and lower limb amputation.
"Obesity is the most important risk factor for type 2 diabetes and our attempts to control rising rates of obesity have so far not proved successful," said Majid Ezzati, a professor at Imperial College London who led the WHO research. 

It is a very unfortunate problem from a health perspective. However, for me as an investor I think it will prove to be an extremely fortunate opportunity to make a ton of money!!!

Anyway, all IMHO and GLTA.
Cheers
Toinv    
Bullboard Posts